Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications

Stock Track04-30

3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.

The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.

Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155891045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155891045","market":"nz","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications","media":"Stock Track","content":"<p>3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.</p><p>The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.</p><p>Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-30 11:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.</p><p>The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.</p><p>Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1155891045","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155891045","pubTimestamp":1777518585,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.The movement is primarily attributed to the latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|三生制药盘中大涨6.03%SSS68注射液获三项适应症IND批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155891045","isCrawlerRequest":true}